Test Catalog

Test ID: MDS1    
Movement Disorder Evaluation, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluating patients with suspected paraneoplastic or other autoimmune movement disorders including patients with ataxia, chorea, dyskinesias, myoclonus, parkinsonism, and stiff-person spectrum

Highlights

Autoimmune movement disorders encapsulate a large and diverse group of neurologic disorders occurring either in isolation or accompanying more diffuse autoimmune encephalitic illnesses.

 

The full range of movement phenomena has been described and, as they often occur in adults, many of the presentations can mimic neurodegenerative disorders, such as Huntington disease. Disorders may be ataxic, hypokinetic (parkinsonism), or hyperkinetic (myoclonus, chorea, and other dyskinetic disorders).

 

The autoantibody targets are diverse and include neuronal surface proteins such as leucine-rich, glioma-inactivated 1 (LGI1), as well as antibodies reactive with intracellular antigens (such as PCA-1) that are markers of a central nervous system process mediated by CD8+ cytotoxic T cells.

 

In some instances (such as Purkinje cell cytoplasmic antibody-1 (PCA-1) autoimmunity), antibodies detected in serum and cerebrospinal fluid can be indicative of a paraneoplastic cause, and may direct the cancer search. In other instances (such as 65-kDa isoform of glutamic acid decarboxylase [GAD65] autoimmunity), a paraneoplastic cause is very unlikely, and early treatment with immunotherapy may promote improvement or recovery.

Profile Information A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test IDReporting NameAvailable SeparatelyAlways Performed
MDSIMovement Disorder Interp, SNoYes
GANGAChR Ganglionic Neuronal Ab, SNoYes
AMPHSAmphiphysin Ab, SNoYes
AGN1SAnti-Glial Nuclear Ab, Type 1NoYes
ANN1SAnti-Neuronal Nuclear Ab, Type 1NoYes
ANN2SAnti-Neuronal Nuclear Ab, Type 2NoYes
ANN3SAnti-Neuronal Nuclear Ab, Type 3NoYes
CS2CSCASPR2-IgG CBA, SNoYes
CRMSCRMP-5-IgG, SNoYes
CRMWSCRMP-5-IgG Western Blot, SYesYes
DPPISDPPX Ab IFA, SNoYes
GD65SGAD65 Ab Assay, SYesYes
LG1CSLGI1-IgG CBA, SNoYes
GL1ISmGluR1 Ab IFA, SNoYes
VGKCNeuronal (V-G) K+ Channel Ab, SNoYes
NMDCSNMDA-R Ab CBA, SNoYes
CCNN-Type Calcium Channel AbNoYes
CCPQP/Q-Type Calcium Channel AbNoYes
PCABPPurkinje Cell Cytoplasmic Ab Type 1NoYes
PCAB2Purkinje Cell Cytoplasmic Ab Type 2NoYes
PCATRPurkinje Cell Cytoplasmic Ab Type TrNoYes

Reflex Tests Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test IDReporting NameAvailable SeparatelyAlways Performed
ABLOTAmphiphysin Western Blot, SNoNo
AMPISAMPA-R Ab IF Titer Assay, SNoNo
AMPCSAMPA-R Ab CBA, SNoNo
DPPTSDPPX Ab IFA Titer, SNoNo
DPPCSDPPX Ab CBA, SNoNo
GABCSGABA-B-R Ab CBA, SNoNo
GABISGABA-B-R Ab IF Titer Assay, SNoNo
GL1CSmGluR1 Ab CBA, SNoNo
GL1TSmGluR1 Ab IFA Titer, SNoNo
NMOFSNMO/AQP4 FACS, SNoNo
NMOTSNMO/AQP4 FACS Titer, SNoNo
NMDISNMDA-R Ab IF Titer Assay, SNoNo
WBNParaneoplastic Autoantibody WBlot,SNoNo

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If IFA suggests Amphiphysin antibody, then Amphiphysin Western blot is performed at an additional charge.

 

If IFA pattern suggest AMPA-R antibody, then AMPA-R AbCBA and AMPA-R titer are performed at an additional charge.

 

If IFA pattern suggests DPPX antibody, then DPPX Ab CBA and DPPX titer are performed at an additional charge.

 

If IFA pattern suggests GABA-B-R antibody, then GABA-B-R Ab CBA and GABA-B-R titer are performed at an additional charge.

 

If IFA pattern suggests mGluR1 antibody, then mGluR1 Ab CBA and mGluR1 titer are performed at an additional charge.

 

If IFA pattern suggests NMDA-R antibody and NMDA-R Ab CBA is positive, then NMDA-R titer are performed at an additional charge.

 

If IFA pattern suggests NMO/AQP4-IgG, then NMO/AQP4-IgG FACS is performed at an additional charge.

 

If NMO/AQP4-IgG FACS screen assay requires further investigation, then NMO/AQP4-IgG FACS titration assay is performed at an additional charge.

 

If indirect immunofluorescence assay (IFA) suggests ANN1S, ANN2S, ANN3S, PCABP, PCAB2, PCATR or AGN1S, then paraneoplastic autoantibody Western blot is performed at an additional charge.

 

See Movement Disorder Evaluation Algorithm, Serum in Special Instructions.

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

ANN1S, ANN2S, ANN3S, PCABP, PCAB2, PCATR, AMPHS, CRMS, AGN1S, DPPIS, DPPTS, GL1IS, GLITS, AMPIS, GABIS, NMDIS: Indirect Immunofluorescence Assay (IFA)

 

AMPCS, GABCS, NMDCS, LG1CS, CS2CS, DPPCS, GL1CS: Cell Binding Assay (CBA)

 

NMOFS, NMOTS: Flow Cytometry (FACS)

 

ABLOT, CRMWS, WBN: Western Blot

 

VGKC, CCN, CCPQ, GANG, GD65S: Radioimmunoassay (RIA)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

No

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

Movement Disorder Evaluation, S

Aliases Lists additional common names for a test, as an aid in searching

Ataxia
Chorea
Stiff-person
Stiff-man
Myoclonus
Parkinsonism
Dyskinesias
PERM